FTC/TAF

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Philadelphia Fight, ViiV Healthcare, Merck Sharp & Dohme LLC

Conditions

HIVHIV InfectionsHIV Preexposure ProphylaxisHiv

Phase 2

Emtricitabine/Tenofovir Alafenamide as Salvage ART

TerminatedNCT02556333

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2015-09-16End: 2016-08-16Updated: 2017-11-14

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

TerminatedNCT04493216

ViiV HealthcareHIV Infections

Start: 2020-11-18End: 2023-05-29Updated: 2024-06-26

Phase 3

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

TerminatedNCT04652700

Merck Sharp & Dohme LLCHIV Preexposure Prophylaxis

Start: 2021-03-15End: 2023-08-04Updated: 2025-01-13

Phase 4

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

CompletedNCT03350672

Philadelphia FightHiv

Start: 2017-11-16End: 2018-05-01Updated: 2021-09-30

Related Papers

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

UNC Libraries2026-03-26

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.

2026-03-14

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

2025-10-17

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Clinical Pharmacology in Drug Development2022-01-075 citations

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

Clinical Infectious Diseases2022-01-0520 citations

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.

2021-05-1812 citations